Skip to content

Substantial, but imperfect adherence a major risk factor for resistance amongst patients starting HAART

WHO: 3 x 5 still on target, 700,000 now on treatment but $2 billion more needed in 2005

US FDA approves coblistered triple combination for developing country use

HCV coinfection linked to faster HIV disease progression in HAART era

Infection with multiple HCV genotypes linked to faster HIV disease progression

Resistance mutations persist for many years in untreated HIV-positive people

Lopinavir/ritonavir not linked to hepatotoxicity regardless of HCV status

Rash no more frequent in Thais treated with NNRTIs than Caucasians

Cases of severe trauma caused during sex reported in HIV-positive men